Allspring Global Investments Holdings LLC Grows Position in DexCom, Inc. (NASDAQ:DXCM)

Allspring Global Investments Holdings LLC increased its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 558.3% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 385,594 shares of the medical device company's stock after purchasing an additional 327,023 shares during the period. Allspring Global Investments Holdings LLC owned approximately 0.10% of DexCom worth $25,958,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Norges Bank purchased a new position in shares of DexCom in the 4th quarter worth approximately $385,367,000. Woodline Partners LP bought a new stake in DexCom in the fourth quarter worth $63,338,000. Northern Trust Corp boosted its stake in DexCom by 22.2% during the fourth quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company's stock worth $322,454,000 after buying an additional 753,857 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in DexCom during the fourth quarter valued at $41,295,000. Finally, GAMMA Investing LLC increased its position in DexCom by 5,951.7% during the first quarter. GAMMA Investing LLC now owns 499,746 shares of the medical device company's stock valued at $34,128,000 after acquiring an additional 491,488 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

DexCom Stock Down 1.0%

NASDAQ:DXCM traded down $0.85 during trading hours on Thursday, reaching $82.73. The company's stock had a trading volume of 1,841,055 shares, compared to its average volume of 4,400,961. The stock has a 50 day moving average price of $82.80 and a two-hundred day moving average price of $79.71. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.32 and a current ratio of 1.50. The company has a market capitalization of $32.44 billion, a P/E ratio of 61.74, a price-to-earnings-growth ratio of 1.78 and a beta of 1.44. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $117.19.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). The company had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a return on equity of 30.05% and a net margin of 12.90%. The company's revenue was up 12.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.32 earnings per share. Equities analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Barclays raised their price objective on shares of DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a research note on Monday, May 5th. Canaccord Genuity Group upped their target price on DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Robert W. Baird reduced their price target on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Finally, Wall Street Zen cut DexCom from a "buy" rating to a "hold" rating in a report on Sunday. Five research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $98.50.

Insider Activity

In other DexCom news, EVP Sadie Stern sold 6,184 shares of the firm's stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total value of $526,320.24. Following the completion of the sale, the executive vice president directly owned 109,621 shares in the company, valued at $9,329,843.31. This trade represents a 5.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction on Monday, June 16th. The shares were sold at an average price of $83.13, for a total value of $228,607.50. Following the sale, the director owned 56,621 shares of the company's stock, valued at approximately $4,706,903.73. This represents a 4.63% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 27,190 shares of company stock worth $2,281,732. Insiders own 0.32% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.